WAY

ANALYST NOTE: WAY (Waystar Holding Corp.) Date: 2026-06-20 Current Price: $18.47

1. Structural Readiness

State: Context-Only (No defined structural coil read) Conservative Entry: — Breakout Level: — Extension: — ATR Current: 5.3% (High)

Analysis:

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Exposure: None Named

At this date, WAY is classified as a TACTICAL, setup-led name. There is no named macro or secular thesis attached to this specific trade setup in the current context. The investment case must be judged strictly on the quality of the business fundamentals and the eventual formation of a technical setup, rather than a pre-existing macro narrative. We do not invent a thesis; we observe the business execution and wait for the market structure to align.

3. The Business

Company Overview: Waystar Holding Corp. operates as a revenue cycle management (RCM) and healthcare payments technology platform. The company serves providers across the entire continuum of care, including physician practices, clinics, surgical centers, laboratories, and large health systems.

Business Model & Evidence:

• Revenue Composition: The business model is highly recurring. As of the 12 months ended March 31, 2026, over 99% of revenue is derived from recurring subscriptions or highly predictable volume-based fees (Evidence E13).
• Scale & Reach: The company serves over 30,000 clients representing over one million distinct providers, including 16 of the top 20 U.S. News Best Hospitals (Evidence E9, E15). In 2025, the platform facilitated over 7.5 billion transactions and processed $2.4 trillion in gross claims volume, covering approximately 60% of U.S. patients (Evidence E10).
• Financial Performance (Q1 2026): For the three months ended March 31, 2026, the company reported:
• Revenue: $313.9 million (up 22.4% YoY) (Evidence E12).
• Net Income: $43.3 million (up from $29.3 million YoY) (Evidence E12).
• Adjusted EBITDA: $135.4 million (up 25.7% YoY) (Evidence E12).
• Guidance: Management reaffirmed full-year 2026 revenue guidance of $1.274 billion to $1.294 billion (midpoint $1.284 billion), representing 17% YoY growth, and Adjusted EBITDA of $530 million to $540 million (midpoint $535 million) (Evidence E2).
• Growth Drivers:
• AI Integration: AI-powered capabilities drove roughly 40% of new bookings in Q1 2026, with clients utilizing the platform for prevention and automation rather than downstream rework (Evidence E3).
• Bookings Quality: Bookings exceeded internal expectations, including a double-digit count of $1 million-plus annual value contracts (Evidence E4).
• Retention: Net Revenue Retention (NRR) for the 12 months ended March 31, 2026, was 110.5% (Evidence E11).
• Market Opportunity: Management views the addressable market as expanding from a $20 billion software base to a potential $100 billion opportunity by embedding "Agentic AI" into mission-critical workflows, moving from software to an autonomous revenue cycle platform (Evidence E6).

4. Archetype and Conviction

Archetype: Growth Leader Fit: The company fits the Growth Leader archetype based on its double-digit revenue growth (22.4% in Q1 2026), expanding margins (EBITDA growth of 25.7%), and high retention rates (110.5% NRR). The business is not a deep value recovery or a cyclical play; it is a compounder leveraging secular tailwinds in healthcare digitization and AI adoption.

Conviction Stack:

• Thesis Strength: Low (Tactical/Setup-led). No macro thesis is currently active.
• Evidence Quality: High. The evidence base is robust, citing specific financials, bookings data, and management guidance from Q1 2026 earnings and filings.
• Structural Quality: Undefined. The business fundamentals are strong, but the technical structure (coil) is missing.
• Rerating Potential: Moderate to High, contingent on the market recognizing the AI-driven expansion of the TAM (from $20B to $100B) and the sustained execution of the 17% growth guidance.

Valuation Context: While specific P/E or EV/EBITDA multiples are not provided in the evidence block, the company is trading at $18.47 with a Q1 2026 run-rate revenue of ~$1.25B and EBITDA of ~$540M. The high volatility (5.3% ATR) suggests the market is pricing in significant uncertainty or potential for rapid re-rating, but without a structural entry point, valuation metrics alone do not constitute a setup.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Fundamental: Continued acceleration in AI-driven bookings (currently 40%) or an expansion of the guidance range beyond the current 17% growth target.
• Market Share: Further evidence of market share gains from competitors following the 2024 cybersecurity incident (Evidence E14).

What Would Invalidate the Case:

• Fundamental: A miss on the $1.274B–$1.294B revenue guidance or a significant drop in Net Revenue Retention below 100%.
• Operational: A failure to deliver on the "48-hour implementation" promise for new clients, which is a key differentiator cited in the evidence.

Gaps in Evidence:

• Valuation Multiples: No current P/E, EV/EBITDA, or forward P/S multiples are provided to contextualize the $18.47 price relative to peers.
• Cash Flow: While EBITDA is provided, free cash flow conversion details are not explicitly detailed in the evidence block.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Q1 2026 revenue growth of 22.4% and EBITDA growth of 25.7%; Net Revenue Retention of 110.5%; AI driving 40% of new bookings. Expected path: Management expects 17% revenue growth and 17% EBITDA growth for 2026; AI capabilities are expected to drive further bookings and market share expansion. Expected horizon: Indefinite until technical structure forms; fundamental thesis plays out over 12-24 months.